Article Sidebar
Published:
Aug 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of co-administration of pranoprofen/emedastine difumarate eye drops on efficacy, inflammatory factors, tear film stability and immune function in children with allergic conjunctivitis
Abstract
Purpose: To investigate the clinical efficacy of pranoprofen eye drops when combined with emedastinedifumarate eye drops for the treatment of children with allergic conjunctivitis.
Methods: A total of 96 children with allergic conjunctivitis admitted to Eye Hospital, China Academy of Chinese Medical Sciences from January 2020 to 2022 were enrolled in this study. They were divided into study group (treated with both pranoprofen eye drops and emedastine difumarate eye drops), and control group (treated with emedastine difumarate eye drops alone), with 48 children in each group. The control group was given emedastine fumarate eye drops 1 drop twice a day. The study group was given pranoprofen eye drops 2 drops 4 times a day in addition to the treatment administered to control group. Patients in both groups were observed and compared after one week of treatment. Efficacy, incidence of adverse reactions, symptom scores, inflammatory factors, tear film stability indicators and immune function indicators were assessed and recorded.
Results: Prior to treatment, there was no significant difference in symptom score, inflammatory factors, tear film stability indicators and immune function indicators between study and control groups. Although the above indicators improved in both groups after treatment, the study group showed significantly greater improvement than control group (p < 0.05). Overall clinical response rate in the study group (95.83 %) was higher than in the control group (77.08 %), while the incidence of adverse reaction in the study group (6.25 %) was lower than that of control group (27.08 %, p < 0.05).
Conclusion: Pranoprofen eye drops, when combined with emedastine difumarate eye drops for treatment of children with allergic conjunctivitis, is more effective than the use of emedastine difumarate eye drops alone. However, further clinical trials are required to validate the findings of this study prior to adoption of the combination treatment in clinical practice.
